drugset / Trial / NCT04435990

Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites

NCT04435990 ↗

Phase 3 Recruiting 150 enrolled Inmunotek S.L. BioClever 2005 S.L. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis/rhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and /or Dermatophagoides farinae.

Timeline

Start
2020-10-06
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject MM09 Other / unclassified 10000 unknown Subcutaneous
Subject MM09 Other / unclassified 30000 unknown Subcutaneous